Alivus Life Sciences Ltd

Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, announced that its board approved a share purchase agreement to acquire a 76% stake in IQGEN-X Pharma Private Limited for an aggregate consideration of approximately Rs 9.12 crores, subject to adjustment as per the share purchase agreement. IQGEN-X Pharma Private Limited, incorporated in October 2016, reported a turnover of Rs 348 lacs for the financial year ended March 31, 2026, and is engaged in the business of formulation development for regulated and semi-regulated markets, with the acquisition expected to provide Alivus Life Sciences a wider spectrum to offer end-to-end solutions in the API and CDMO space.

Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, will hold its Fifteenth Annual General Meeting on September 8, 2026, at 3:00 p.m. IST, and the board of directors has recommended a final dividend of Rs 5.00 per equity share of Rs 2 each for the financial year ended March 31, 2026, with a record date of September 1, 2026, and payment expected to be made on or after September 11, 2026.

Net profit of Alivus Life Sciences rose 31.71% to Rs 160.08 crore in the quarter ended June 2026 as against Rs 121.54 crore during the previous quarter ended June 2025. Sales rose 6.41% to Rs 640.41 crore in the quarter ended June 2026 as against Rs 601.85 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales640.41601.85 6 OPM %33.0628.63 - PBDT232.81180.05 29 PBT212.22162.99 30 NP160.08121.54 32 Powered by Capital Market - Live

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) announced that its board of directors approved the allotment of 32,000 equity shares of Rs 2 face value each to eligible employees who exercised stock options under the ‘Employee Stock Option Scheme, 2021’, increasing the company's paid-up share capital from 12,27,39,448 equity shares aggregating to Rs 24,54,78,896 to 12,27,71,448 equity shares aggregating to Rs 24,55,42,896.

Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, announced a net profit after tax of Rs 1,601 million for the first quarter ended June 30, 2026, a 31.8% year-over-year increase, alongside revenue from operations of Rs 6,404 million, up 6.4% year-over-year, driven by a 26.5% year-over-year growth in its non-GPL business. The company reported earnings before interest, taxes, depreciation, and amortization of Rs 2,341 million, a 29.1% year-over-year increase, with margins at 36.6%, and held cash and cash equivalents of Rs 8,802 million as of June 30, 2026.

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 30 July 2026.

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 30 July 2026.

Profit before tax (PBT) rose 12.81% YoY to Rs 215.79 crore in Q4 FY26. EBITDA stood at Rs 237.3 crore, registering the growth of 13.8%, compared with Rs 208.5 crore posted in Q4 FY25. EBITDA margin improved to 34.4% in Q4 FY26 as against 32.1% in Q4 FY25. Revenue from generic API segment rose 6.77% to Rs 634.3 crore while revenue from CDMO segment stood at Rs 45.3 crore, up 4.38% from 43.4 crore recorded in Q4 FY25. On full year basis, the company's standalone net profit climbed 16.24% to Rs 564.48 crore on 6.91% rise in revenue from operations to Rs 2551.83 crore in FY26 over FY25. During FY26, the company generated a strong free cash flow of Rs 259 crore leading to cash and cash equivalents (including short term investments) of Rs 782.4 crore as of March 31, 2026. Yasir Rawjee, MD & CEO, Alivus Life Sciences, said, 'The past two years under Nirma's ownership have been deeply fulfilling ' a period of transition and evolution that has strengthened the foundation of the business and positioned us decisively for the next phase of sustainable growth. Coming to our results, FY26 reflected a clear improvement in our operating performance. Revenue grew 6.9% year-on-year, supported by growth in non-GPL business of 13%, which resulted in EBITDA growth of 19.6%. Encouragingly, the CDMO business delivered the turnaround we had planned in the second half, closing the year with 18% YoY growth. We also witnessed healthy momentum across key geographies like India, Europe, ROW, Japan and LATAM, while the GPL business de-grew by 4.9% For FY27, we remain confident of delivering high single-digit revenue growth, with margins sustained above 30%, supported by improving operating leverage and a rising contribution from new products.' Tushar Mistry, CFO, Alivus Life Sciences, said, 'For the full year, we reported EBITDA margins of 33.6%, exceeding our guided range of 30'32%, driven by a favourable product mix and disciplined control over operating expenses.' Meanwhile, the company's board recommended payment of final equity dividend of Rs 5 per equity share of face value Rs 2 each for FY26. Alivus Life Sciences (formerly Glenmark Life Sciences) is engaged in the development and manufacturing of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes.Powered by Capital Market - Live

Profit before tax (PBT) rose 12.81% YoY to Rs 215.79 crore in Q4 FY26. EBITDA stood at Rs 237.3 crore, registering the growth of 13.8%, compared with Rs 208.5 crore posted in Q4 FY25. EBITDA margin improved to 34.4% in Q4 FY26 as against 32.1% in Q4 FY25. Revenue from generic API segment rose 6.77% to Rs 634.3 crore while revenue from CDMO segment stood at Rs 45.3 crore, up 4.38% from 43.4 crore recorded in Q4 FY25. On full year basis, the company's standalone net profit climbed 16.24% to Rs 564.48 crore on 6.91% rise in revenue from operations to Rs 2551.83 crore in FY26 over FY25. During FY26, the company generated a strong free cash flow of Rs 259 crore leading to cash and cash equivalents (including short term investments) of Rs 782.4 crore as of March 31, 2026. Yasir Rawjee, MD & CEO, Alivus Life Sciences, said, 'The past two years under Nirma's ownership have been deeply fulfilling ' a period of transition and evolution that has strengthened the foundation of the business and positioned us decisively for the next phase of sustainable growth. Coming to our results, FY26 reflected a clear improvement in our operating performance. Revenue grew 6.9% year-on-year, supported by growth in non-GPL business of 13%, which resulted in EBITDA growth of 19.6%. Encouragingly, the CDMO business delivered the turnaround we had planned in the second half, closing the year with 18% YoY growth. We also witnessed healthy momentum across key geographies like India, Europe, ROW, Japan and LATAM, while the GPL business de-grew by 4.9% For FY27, we remain confident of delivering high single-digit revenue growth, with margins sustained above 30%, supported by improving operating leverage and a rising contribution from new products.' Tushar Mistry, CFO, Alivus Life Sciences, said, 'For the full year, we reported EBITDA margins of 33.6%, exceeding our guided range of 30'32%, driven by a favourable product mix and disciplined control over operating expenses.' Meanwhile, the company's board recommended payment of final equity dividend of Rs 5 per equity share of face value Rs 2 each for FY26. Alivus Life Sciences (formerly Glenmark Life Sciences) is engaged in the development and manufacturing of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. The counter declined 1.68% to settle at Rs 1,044.85 on the BSE.Powered by Capital Market - Live

Alivus Life Sciences announced that the Board of Directors of the Company at its meeting held on 14 May 2026, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 250%) , subject to the approval of the shareholders.